Moving to the Forefront of Medicine is Immunolgy & Immunotherapies via Stem Cell

Regen BioPharma, Inc (OTC:RGBP-RGBPP) is a small company that is focused on the immunology & immunotherapy space. Their NR2F6 program is leading the way.

They are we believe the only company utilizing Small Molecules in the space. RGBP has been methodically optimizing small molecules that bind to, and activate the NR2F6 Nuclear Receptor.

The process is close to completion, with primary and back up compounds being readied for final animal Pre-Clinical experiments. This is an important Milestone and they look forward to the next phase of drug development.

The NR2F6 Receptor has been identified as a potentially, most important Immune Cell Inhibitor and Cancer Stem Cell Differentiator. The goal is unleashing the Cancer-Killing Potential of one's Own Immune System as well as identifying Agonists which Should Suppress the Immune System in diseases where the immune system is over activated, such as Autoimmunity.

The company is focused on Rapidly advancing Dynamic Novel Technologies or Drugs, Treatments and Therapies through Pre Clinical & Phase I/II Clinical Trials. Their Focus is various Cancers & Auto Immune Disorders.

Ex-Vivo Trials have concluded their Lead Drug RG-NAH005 has presented a Safety Profile of Non Toxicity in a Maximum Dose, Larger & Smaller repeat Dosing as well, that allows for them to move to the next phase. 

Using Patient's Own Immune Systems RGBP has shown the ability to Reduce Tumors and unleash potential Cancer Killing Effects.

Later assays have identified additional small molecule inhibitors (3) bringing the total number to (5) now.

Previously they have proven an ability to suppress Auto Imunes like Rheumatoid Arthritis, Crohn's & Lupus, then Ulcerative Colitis & Irritable Bowel.

RGBP reportted that their researchers determinatined Combining it's Lead NR2F6 Small Molecule Agonist with Cannabidiol's (CBD's) may provide a Dynamic Non Steroidal Therapy for treating (IBD) Inflammatory Bowel Disease.

The Inclusion & Augmentaion of CBD's in Trials May Improve All Patient Outcomes in their Cancer and Auto Immune Studies.

Regen has advanced rather rapidly the last few years, It could be setting itself up as a potential future Merge/Buyou Target.

For more Information & Links to All of the News & PR's visit:

https://finance.yahoo.com/quote/RGBP?p=RGBP&.tsrc=fin-srch 

You may also like to contact for more information:

Robert E. Kreh – Principal

Small Cap Solutions, LLC

robkreh@smallcapsolutions.com  

(443) 567-2609

https://www.smallcapsolutions.com 

( OTC:RGBP -) Disclaimer: This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at . Small Cap Solutions, LLC has received payment in cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker( S )/Broker Dealer with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure:  I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.